Aspen Neuroscience raises $141M IPO for Parkinson's cell therapy

· Health · United States · Japan

Aspen Neuroscience, a San Diego biotechnology startup developing a cell therapy for Parkinson's disease, raised $141 million in an initial public offering, joining the public markets on Friday amid a sizzling IPO streak for drug developers. The company is one of several firms working on a cutting-edge technique with the potential to slow or even halt the neurodegenerative condition. The listing coincides with a separate milestone in the field: a patient has undergone pioneering stem-cell therapy to treat Parkinson's disease, according to the Japanese drugmaker behind the treatment, in a world first following its conditional approval in Japan. Together the developments signal growing momentum for cell-based approaches to a disease that currently has no disease-modifying treatment.

Why it matters：Two simultaneous signals — a public listing and a first-in-world stem-cell treatment — suggest cell therapy for Parkinson's is moving from research toward commercial and clinical reality, a space several biotechs are racing to lead.

Key points

  • Aspen raised $141 million in its IPO on Friday.
  • The company's lead program is a cell therapy for Parkinson's disease.
  • A Japanese drugmaker reported a world-first stem-cell treatment for Parkinson's after conditional approval in Japan.

Sources (original reporting)

More stories from this day